AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02286479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
Study NCT02286479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop drainage
Description: In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
Study NCT04863807 — intervention group
Intervention type: PROCEDURE
Intervention: Regional Anaesthesia
Description: Thoracic epidural/Erector Spinae block/Serratus Anterior block
Study NCT00696566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Rifampicin
Description: Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days
Study NCT03166956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glutamine and vitamin C enteral supplement
Description: Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
Study NCT03166956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine and vitamin C enteral supplement
Description: Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
Study NCT02228122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquacel® Ag+ Extra
Description: Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
Study NCT02029547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)
Description: No Florbetapir (18F) will be administered in this study.
Study NCT01640561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISC
Description: The Mediational Interventions for Sensitizing Caregivers
Study NCT01640561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UCOBAC
Description: This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
Study NCT03074643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss intervention months 0-6
Description: All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
Study NCT03074643 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss intervention months 0-6
Description: All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
Study NCT03074643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention months 0-6
Description: All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
Study NCT03074643 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise intervention months 0-6
Description: All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
Study NCT03074643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate supplement for months 0-6
Description: Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (\~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
Study NCT03074643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein supplement for months 0-6
Description: Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
Study NCT03074643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein supplement for follow-up months 7-18
Description: Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
Study NCT03983005 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-B-FNA
Description: Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
Study NCT02919605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Pentamidine
Description: The patients will come to the hospital to take a single dose of the Pentamidine.
Study NCT02919605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two doses of Pentamidine
Description: The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
Study NCT02919605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three doses of Pentamidine
Description: The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
Study NCT02079870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
Study NCT02079870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Solution for subcutaneous (s.c. - under the skin) injection
Study NCT03400553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood analysis
Description: The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
Study NCT01677065 — intervention group
Intervention type: DRUG
Intervention: Oxycodone controlled-release test formulation
Description: single dose administration of test formulation under fasted conditions
Study NCT01677065 — intervention group
Intervention type: DRUG
Intervention: Immediate-release reference drug
Description: single dose administration of reference drug under fasted conditions
Study NCT04807530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
Study NCT04807530 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TMS
Description: The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
Study NCT00231933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered planning (PCP)
Description: PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
Study NCT00231933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community integration (CI)
Description: CI includes recovery group sessions and community integration activities.
Study NCT00231933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Illness management recovery (IMR)
Description: IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
Study NCT00231933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness management recovery (IMR)
Description: IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
Study NCT02117817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT02350543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT01954290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
Study NCT01954290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
Study NCT01954290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
Study NCT03616743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation about the links between smoking and chronic pain.
Study NCT03616743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief smoking control arm
Description: Psychoeducation about the general adverse effects of smoking.
Study NCT03338556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001
Study NCT03338556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02117817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabpaclitaxel
Description: Given IV
Study NCT02786862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: independent ventilation
Description: comparison conventional and independent 1:1 ventilation
Study NCT03232112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 MG Injection
Description: Subcutaneous injection once-weekly
Study NCT03232112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BD PosiFlush (saline)
Description: Subcutaneous injection once-weekly
Study NCT01912885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 1-1
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
Study NCT01912885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 1-2
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
Study NCT01912885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 2-1
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
Study NCT01912885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 2-2
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
Study NCT01912885 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS 0-1
Description: Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
Study NCT01809236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: intravitreal injection of 0.5 mg Conbercept
Study NCT03283839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Posturography
Description: Evaluation of postural control and of orientation function
Study NCT03910192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based coaching
Description: 16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
Study NCT03910192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary cardiovascular risk reduction coaching
Description: Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
Study NCT02997124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local infiltration and TAP block
Description: Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
Study NCT02997124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local infiltration only
Description: Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
Study NCT03877744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive virtual presence
Description: parents will install car seat through remote guidance via interactive virtual presence
Study NCT03877744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: live technician
Description: parents will install car seat through guidance from a live certified technician who is present
Study NCT03868722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
Study NCT03868722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comtan®
Description: 200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
Study NCT03103399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
Study NCT04289883 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nano-particulated whey protein vs non-particulated whey protein (control)
Description: Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
Study NCT04289883 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High molecular weight whey protein-alginate coacervates vs calcium alginate (control)
Description: Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
Study NCT02214173 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice bran arabinoxylan compound (RBAC)
Description: 2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
Study NCT02214173 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
Study NCT03730389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Physical Vibration Lithecbole (EPVL)
Description: Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
Study NCT02363647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor Genomic Analysis
Description: Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process.
Study NCT03933501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and metronidazole
Description: 375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
Study NCT01145222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. CNS 7056
Description: Initial low dose plus supplemental doses as necessary.
Study NCT01145222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. CNS 7056
Description: Initial intermediate dose plus supplemental doses as necessary.